TimothyChung-TinWongMDMS

Cardiology • Oakland, PA

Cardiothoracic Imaging

Assistant Professor of Medicine, University of Pittsburgh School of Medicine Director, UPMC HVI Hypertrophic Cardiomyopathy Center; Director, UPMC HVI Cardiovascular Magnetic Resonance Center

Join to view full profile

Dr. Wong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wong's full profile

Already have an account?

Office
UPMC Presbyterian
200 Lothop St. 5B Outpatient Cardiology Clinic
Oakland, PA 15213
Phone+1 412-647-6176

Fax+1 412-647-9773

Summary

Dr. Timothy Wong is a cardiologist in Pittsburgh, PA and is affiliated with multiple hospitals in the area, including UPMC Magee-Womens Hospital, UPMC Presbyterian, UPMC Children's Hospital of Pittsburgh, and UPMC Passavant. He received his medical degree from NYU School of Medicine and has been in practice 15 years. He specializes in hypertrophic cardiomyopathy and advanced cardiac imaging (including cardiac MRI, echocardiography, and nuclear cardiology).

Education & Training

UPMC Medical EducationFellowship, Cardiovascular Disease, 2006 - 2009
NYU Grossman School of MedicineResidency, Internal Medicine, 2002 - 2006
New York University School of MedicineClass of 2002

Certifications & Licensure

PA State Medical License 2006 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) Start of enrollment: 2018 Mar 30
Completed
Phase 2
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Start of enrollment: 2018 May 29
Completed
Phase 3
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM Start of enrollment: 2018 Oct 05
Active, not recruiting
Phase 2, Phase 3
Dose-finding Study to Evaluate the Safety, Tolerability, PK, and PD of CK-3773274 in Adults With HCM Start of enrollment: 2020 Jan 10
Completed
Phase 2
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM Start of enrollment: 2021 May 06
Enrolling by invitation
Phase 2
Join now to see all

Publications & Presentations

PubMed

6 citations
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.
Ahmad Masri, Mark V Sherrid, Theodore P Abraham, Lubna Choudhury, Pablo Garcia-Pavia
Journal of Cardiac Failure. 2024-11-01
Atrial Fibrillation in Hypertrophic Cardiomyopathy.
Adaya Weissler-Snir, Sara Saberi, Timothy C Wong, Antonis Pantazis, Anjali Owens
JACC. Advances. 2024-09-01
Remote myocardial fibrosis predicts adverse outcome in patients with myocardial infarction on clinical cardiovascular magnetic resonance imaging.
Nicholas Black, Joshua Bradley, Erik B Schelbert, Laura J Bonnett, Gavin A Lewis
Journal of Cardiovascular Magnetic Resonance. 2024-07-23

Lectures

Needle Knives and Screws: Challenges and Conundrums in HCM
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019

Press Mentions

Pitt Football Coach Praises Doctors for Preventing TragediesAugust 10th, 2016

Professional Memberships

American College of Cardiology - ACC
Member